40 likes | 188 Vues
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: efficacy and safety of ivabradine . A SHIFT study analysis.
E N D
Systolic Heart failure treatment withthe Ifinhibitor ivabradineTrial Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: efficacy and safety of ivabradine. A SHIFT study analysis TavazziL, et al. Int J Cardiol. 2013. Dec 10;170(2):182-188 www.shift-study.com
50 45 40 COPD (placebo) COPD (ivabradine) 35 30 Non-COPD (placebo) Patients (%) 25 Non-COPD (ivabradine) 20 15 10 5 0 0 6 12 18 24 Time (months) Effect of ivabradine on composite of CV death or HF hospitalization Ivabradine is safe and effective in lowering the relative risk of the primary composite end point in both COPD and non-COPD patients www.shift-study.com Tavazzi L et al. Int J Cardiol. 2013. Dec 10;170(2):182-188